Studies of glucose-insulin-potassium (GIK) infusions and glucagon-like peptide (GLP-1) agonists which aim to increase insulin secretion, sensitivity, and glucose uptake have suggested an improvement in cardiac function in patients with ischaemic cardiomyopathy in settings of an acute myocardial infarction [53, 54]. This evidence concerns the gene INS and myocardial infarction.